drugset / Trial / NCT00705549
Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
Phase 2
Terminated
88 enrolled
Hellenic Oncology Research Group
University Hospital of Crete · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective pilot phase II trial, in patients with wet stage IIIb and IV NSCLC using chemotherapy regimens which will be defined according to the pharmacogenomic profile (tumoral expression of ERCC1, BRCA1 and RRM1) of the tumor cells.
Timeline
- Start
- 2008-02
- Primary completion
- 2011-09
- Completion
- 2011-09
Outcome
Outcome not reported
Stopped (Enrollment): “Due to poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Pemetrexate | Unknown | 500 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 50 mg | Oral |